| Name | Title | Contact Details |
|---|---|---|
Lisa Higgins |
General Counsel | Profile |
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Valir Health is a comprehensive healthcare organization specializing in a full range of medical services. Our entities include a physical rehabilitation hospital, 15 physical therapy clinics, a hospice division, a fitness center, (PACE) a Program of All-inclusive Care for the Elderly, acupuncture clinic, corporate health and safety services and programs, and medical consulting and billing services. Valir Health provides uncompromised service to each patient and client we serve, we are committed to establishing a higher standard through strength, courage, and character. Driven by our motto, "Do the right thing," Valir has continued to grow through positive physician and patient referrals and strong business relationship development.
SignalPET offers advanced artificial intelligence-supported veterinary radiology. See how SignalPET can make a difference for your practice.
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA cleared as a tool used in the treatment of inflammatory skin conditions, including psoriasis, atopic dermatitis, and leukoderma.
Genomics Institute of the Novartis Research Foundation (GNF) is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.